Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study.

Masatoshi KudoKaoru TsuchiyaNaoya KatoAtsushi HagiharaKazushi NumataHiroshi AikataYoshitaka InabaShunsuke KondoKenta MotomuraJunji FuruseMasafumi IkedaManabu MorimotoMeguru AchiraShingo KurodaAkiko Kimura

Published in: Journal of gastroenterology (2021)

Cabozantinib 60 mg/day has a favorable benefit/risk profile for Japanese patients with advanced HCC who have previously received one or two lines of systemic anticancer therapy including sorafenib. (Clinical trial registration: NCT03586973).

Keyphrases

clinical trial
metastatic renal cell carcinoma
phase ii
open label
study protocol
randomized controlled trial
stem cells
cell therapy
smoking cessation